Biotech ex­ecs urge in­dus­try to sup­port ac­cess to gen­der-af­firm­ing care, as­sist work­ers amid rush of an­ti-LGBTQ bills

More than 60 biotech ex­ec­u­tives signed a let­ter call­ing on their in­dus­try coun­ter­parts to op­pose an­ti-gen­der-af­firm­ing care leg­is­la­tion and sup­port LGBTQ+ work­ers and re­gion­al ad­vo­ca­cy groups. The ex­ec­u­tives al­so urge in­dus­try lead­ers to re­con­sid­er ex­ist­ing or planned foot­prints in states with poli­cies at­tack­ing the trans­gen­der com­mu­ni­ty.

Those who signed the let­ter in­clude start­up CEOs, board mem­bers of the Biotech­nol­o­gy In­no­va­tion Or­ga­ni­za­tion like Paul Hast­ings and Grace Colón, and decades-long ex­ec­u­tives who have al­so spo­ken out about the over­turn­ing of Roe v. Wade and the mifepri­s­tone le­gal bat­tle.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER